ACCESS Newswire

NLS Pharmaceutics AG

Share
NLS Pharmaceutics Announces Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P.
  • Financing provided exclusively by leading healthcare fund BVF Partners L.P.
  • Cash runway potentially secured beyond pivotal studies and NDA submission for Quilience® (Mazindol ER) in narcolepsy

ZURICH, SWITZERLAND / ACCESSWIRE / December 14, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP,)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced the closing of its previously publicized purchase agreement with BVF Partners L.P. ("BVF") comprised of an initial closing of $10 million in exchange for 11,494,253 common shares (or equivalents), representing a purchase price per share of $0.87.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

As part of the financing, in a second potential closing, BVF will have the right, following a successful end of phase 2 meeting with the U.S. Food and Drug Administration ("FDA"), among other closing conditions, to purchase units at a per unit purchase price of $1.50, which units will consist of common shares (or equivalents), as well as a common share warrant to purchase up to one and a half common shares at an exercise price of $2.03 per share. If this option is exercised in full, BVF will receive 20 million common shares plus common share warrants to purchase 20 million NLS common shares at $2.03 per share.

Laidlaw & Company (UK) Ltd. acted as exclusive introducing broker for the offering.

NLS intends to use the net proceeds from the offering to accelerate the ongoing clinical development of its lead product, Mazindol ER for the treatment of narcolepsy, to advance NLS-4 and other product candidates, to support business development and licensing activities, and for general corporate purposes. With this financing, NLS expects to be able to fund its operations through 2025, beyond the anticipated submission of its New Drug Application for Mazindol ER in narcolepsy, expected in late 2024 or early 2025.

The offering is being made in the United States pursuant to the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D as promulgated by the Securities and Exchange Commission (the "SEC"). The Securities have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and accordingly may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the common shares and common shares issuable upon the exercise of the warrants.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience®, is a proprietary extended-release formulation of Mazindol (Mazindol ER) and is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders such as idiopathic hypersomnia (IH), for which NLS recently obtained Orphan Disease Designation (ODD) from the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Mazindol is a triple monoamine reuptake inhibitor and partial Orexin-2 Receptor agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. A Phase 2 multi-center U.S. clinical trial evaluating Quilience® in adult subjects suffering from narcolepsy met its primary endpoint with high statistical significance and demonstrated a favorable safety and tolerability profile. NLS also successfully completed a Phase 2 study in the U.S. evaluating Nolazol® (Mazindol Controlled-Release) in adult subjects suffering from ADHD. The study met all primary and secondary endpoints and Nolazol® was well-tolerated. Quilience® has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy. Up to 1/3 of narcoleptic patients are also diagnosed with ADHD.

Safe Harbor Statement

This press release contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements when it discusses the intended use of proceeds, its expected cash runway, the timing of its New Drug Application for Quilience and the prospect of a second closing. These forward-looking statements and their implications are based on the current expectations of the management of NLS only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles in launching and/or successfully completing its clinical trials; NLS' products may not be approved by regulatory agencies, NLS' technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with NLS' process; NLS' products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS' patents may not be sufficient; NLS' products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting NLS is contained under the heading "Risk Factors" in NLS' annual report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC), which is available on the SEC's website, www.sec.gov, and in subsequent filings made by NLS with the SEC.

For additional information:

Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
www.nlspharmaceutics.com

###

SOURCE: NLS Pharmaceutics AG



View source version on accesswire.com:
https://www.accesswire.com/731772/NLS-Pharmaceutics-Announces-Closing-of-Initial-Tranche-of-US100-Million-Purchase-Agreement-with-BVF-Partners-LP

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Loar Holdings Inc. Reports Q1 2025 Record Results and Upward Revision to 2025 Outlook13.5.2025 08:30:00 CEST | Press release

WHITE PLAINS, NY / ACCESS Newswire / May 13, 2025 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reported record results for the first quarter of 2025. First Quarter 2025 Net sales of $114.7 million, up 24.8% compared to the prior year's quarter. Net income of $15.3 million, up $13.1 million compared to the prior year's quarter. Diluted earnings per share of $0.16. Adjusted EBITDA of $43.1 million, up 30.6% compared to the prior year's quarter. Net income margin for the quarter improved to 13.4% compared to the prior year's quarter net income margin of 2.4%. Adjusted EBITDA Margin for the quarter improved to 37.6% compared to 36.0% for the prior year's quarter. Adjusted Earnings Per Share of $0.20. "We began 2025 with excellent momentum from strong demand across our end-markets," stated Dirkson Charles, Loar CEO and Executive Co-Chairman of the Board of Directors. "In the quarter, sales to our Original Equipment, Commercial Aftermarket and Defense marke

OMP's Unison Planning Achieves SAP(R) Certified Integration with RISE with SAP S/4HANA(R) Cloud13.5.2025 07:00:00 CEST | Press release

ANTWERPEN, BE / ACCESS Newswire / May 13, 2025 / OMP, a global leader in supply chain planning solutions, announced today that its Unison PlanningTM platform has achieved SAP® certification as integrated with RISE with SAP S/4HANA® Cloud. Continuing its long history of providing SAP-certified integration, this milestone confirms Unison Planning's full support for S/4HANA environments and its compatibility with RISE with SAP. The integration delivers seamless, near-real-time connectivity between SAP and Unison Planning's advanced supply chain capabilities, reinforcing OMP's role as a trusted partner for navigating complex planning environments. "Achieving this certification highlights our commitment to innovation and enterprise-grade reliability," says Tom Wouters, Chief Product Officer at OMP. "It confirms our ability to support global businesses in their digital transformation journeys, especially those migrating to S/4HANA with RISE with SAP." OMP was recently recognized as a Leader

BioNxt Reports Expanded Research, Development and Commercialization Capability with Centralized Munich Laboratory13.5.2025 03:05:00 CEST | Press release

VANCOUVER, BC / ACCESS Newswire / May 13, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, is pleased to announce the integration of its research, development and commercialization activities to the Gen-Plus GmbH & Co. KG (Gen-Plus) Contract Research and Development Organization (CRDO) in Munich, Germany. The move provides BioNxt with enhanced R&D capabilities, collaboration opportunities, and accelerated innovation potential within a major European biotech hub. The Company seeks to leverage the advanced and innovative infrastructure of the Gen-Plus Laboratory and harness the facility's 1,000 square meters of state-of-the-art space designed for high-potency active pharmaceutical ingredients and GMP-compliant processes. The lab's specialized equipment, including advanced technologies for solid and semi-solid dosage forms and capabilities in drug printing, will empower BioNxt

Market Logic Software and Alchemy-RX Announce Strategic Partnership to Accelerate Transformation of Insights to Growth13.5.2025 02:00:00 CEST | Press release

BERLIN, DE / ACCESS Newswire / May 13, 2025 / Market Logic Software, the market-leading SaaS provider of insight management solutions, announces a strategic partnership with Alchemy-Rx, a growth consultancy. Together, the two firms will help brands unlock the full value of insights - transforming research and data into topline growth. This partnership brings together complementary capabilities: Market Logic's AI-powered technology platform DeepSights™ - which centralizes and synthesizes research across knowledge sources - and Alchemy-Rx's proven methods to turning those insights into high-impact ideas. While Market Logic enables organizations to uncover trusted insights faster and more effectively, Alchemy-Rx helps brands act on those insights to fuel incremental revenue. "DeepSights is best-in-class-when it comes to insight management," said Richard Davies, Co-Founder of Alchemy-Rx. "This partnership combines our strengths. Making sense of multiple data sources to discover an insight

MicroVision Announces First Quarter 2025 Results12.5.2025 16:05:00 CEST | Press release

REDMOND, WA / ACCESS Newswire / May 12, 2025 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announced its first quarter 2025 results. Key Business Highlights Established defense industry advisory board to accelerate strategic expansion and pursuit of revenue opportunities in the defense tech and military sectors. Elevated momentum toward near-term revenue opportunities from multiple leading industrial companies in the autonomous mobile robot (AMR) and automated guided vehicle (AGV) sector. Deepened executive leadership expertise, onboarding Glen DeVos, former CTO of Aptiv, as MicroVision's Chief Technology Officer, leading the Company's innovative product roadmapping and enhanced go-to-market strategy. Continued engagement with top-tier global automotive OEMs, with seven high-volume RFQs for passenger vehicles and custom development opportunities. Ramped production to meet anticipated volume demand, ensur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye